Drug Trial Radar · NCT06104839
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
73
Planned (sponsor's estimate)
Start
Sep 1, 2024
Primary completion
Oct 31, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- NEXTGEN BioscienceIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Conditions
- Alopecia Areata
Interventions
NXC736Drug
oral administration
PlaceboDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change(%) in SALT score from baseline at Week 12Time frame: 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital.
Seoul, South Korea · Recruiting
Kyung Hee University Hospital at Gangdong
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.